345 related articles for article (PubMed ID: 21788345)
1. Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells.
Nierkens S; den Brok MH; Garcia Z; Togher S; Wagenaars J; Wassink M; Boon L; Ruers TJ; Figdor CG; Schoenberger SP; Adema GJ; Janssen EM
Cancer Res; 2011 Oct; 71(20):6428-37. PubMed ID: 21788345
[TBL] [Abstract][Full Text] [Related]
2. Plasmacytoid dendritic cells cross-prime naive CD8 T cells by transferring antigen to conventional dendritic cells through exosomes.
Fu C; Peng P; Loschko J; Feng L; Pham P; Cui W; Lee KP; Krug AB; Jiang A
Proc Natl Acad Sci U S A; 2020 Sep; 117(38):23730-23741. PubMed ID: 32879009
[TBL] [Abstract][Full Text] [Related]
3. Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice.
Nierkens S; den Brok MH; Roelofsen T; Wagenaars JA; Figdor CG; Ruers TJ; Adema GJ
PLoS One; 2009 Dec; 4(12):e8368. PubMed ID: 20020049
[TBL] [Abstract][Full Text] [Related]
4. Granzyme A Stimulates pDCs to Promote Adaptive Immunity via Induction of Type I IFN.
Shimizu K; Yamasaki S; Sakurai M; Yumoto N; Ikeda M; Mishima-Tsumagari C; Kukimoto-Niino M; Watanabe T; Kawamura M; Shirouzu M; Fujii SI
Front Immunol; 2019; 10():1450. PubMed ID: 31293597
[TBL] [Abstract][Full Text] [Related]
5. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice.
Liu C; Lou Y; Lizée G; Qin H; Liu S; Rabinovich B; Kim GJ; Wang YH; Ye Y; Sikora AG; Overwijk WW; Liu YJ; Wang G; Hwu P
J Clin Invest; 2008 Mar; 118(3):1165-75. PubMed ID: 18259609
[TBL] [Abstract][Full Text] [Related]
6. CpG-A stimulates Hsp72 secretion from plasmacytoid dendritic cells, facilitating cross-presentation.
Tanaka T; Kajiwara T; Kutomi G; Kurotaki T; Saito K; Kanaseki T; Tsukahara T; Hirohashi Y; Torigoe T; Hirata K; Okamoto Y; Sato N; Tamura Y
Immunol Lett; 2015 Sep; 167(1):34-40. PubMed ID: 26141624
[TBL] [Abstract][Full Text] [Related]
7. Conventional but not plasmacytoid dendritic cells foster the systemic virus-induced type I IFN response needed for efficient CD8 T cell priming.
Hervas-Stubbs S; Riezu-Boj JI; Mancheño U; Rueda P; Lopez L; Alignani D; Rodríguez-García E; Thieblemont N; Leclerc C
J Immunol; 2014 Aug; 193(3):1151-61. PubMed ID: 24973449
[TBL] [Abstract][Full Text] [Related]
8. Human Plasmacytoid and Monocyte-Derived Dendritic Cells Display Distinct Metabolic Profile Upon RIG-I Activation.
Fekete T; Sütö MI; Bencze D; Mázló A; Szabo A; Biro T; Bacsi A; Pazmandi K
Front Immunol; 2018; 9():3070. PubMed ID: 30622542
[TBL] [Abstract][Full Text] [Related]
9.
Cheng Y; Lemke-Miltner CD; Wongpattaraworakul W; Wang Z; Chan CHF; Salem AK; Weiner GJ; Simons AL
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060147
[TBL] [Abstract][Full Text] [Related]
10. TLR9-Activating CpG-B ODN but Not TLR7 Agonists Triggers Antibody Formation to Factor IX in Muscle Gene Transfer.
Butterfield JSS; Biswas M; Shirley JL; Kumar SRP; Sherman A; Terhorst C; Ling C; Herzog RW
Hum Gene Ther Methods; 2019 Jun; 30(3):81-92. PubMed ID: 31140323
[TBL] [Abstract][Full Text] [Related]
11. Facilitated antigen uptake and timed exposure to TLR ligands dictate the antigen-presenting potential of plasmacytoid DCs.
Kool M; Geurtsvankessel C; Muskens F; Madeira FB; van Nimwegen M; Kuipers H; Thielemans K; Hoogsteden HC; Hammad H; Lambrecht BN
J Leukoc Biol; 2011 Dec; 90(6):1177-90. PubMed ID: 21934071
[TBL] [Abstract][Full Text] [Related]
12. Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy.
Kuai R; Sun X; Yuan W; Ochyl LJ; Xu Y; Hassani Najafabadi A; Scheetz L; Yu MZ; Balwani I; Schwendeman A; Moon JJ
J Control Release; 2018 Jul; 282():131-139. PubMed ID: 29702142
[TBL] [Abstract][Full Text] [Related]
13. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells.
Drobits B; Holcmann M; Amberg N; Swiecki M; Grundtner R; Hammer M; Colonna M; Sibilia M
J Clin Invest; 2012 Feb; 122(2):575-85. PubMed ID: 22251703
[TBL] [Abstract][Full Text] [Related]
14. Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants.
Ali OA; Verbeke C; Johnson C; Sands RW; Lewin SA; White D; Doherty E; Dranoff G; Mooney DJ
Cancer Res; 2014 Mar; 74(6):1670-81. PubMed ID: 24480625
[TBL] [Abstract][Full Text] [Related]
15. Despite Increased Type 1 IFN, Autoimmune Nonobese Diabetic Mice Display Impaired Dendritic Cell Response to CpG and Decreased Nuclear Localization of IFN-Activated STAT1.
Rahman MJ; Rahir G; Dong MB; Zhao Y; Rodrigues KB; Hotta-Iwamura C; Chen Y; Guerrero A; Tarbell KV
J Immunol; 2016 Mar; 196(5):2031-40. PubMed ID: 26826238
[TBL] [Abstract][Full Text] [Related]
16. Mycobacterium tuberculosis and TLR2 agonists inhibit induction of type I IFN and class I MHC antigen cross processing by TLR9.
Simmons DP; Canaday DH; Liu Y; Li Q; Huang A; Boom WH; Harding CV
J Immunol; 2010 Aug; 185(4):2405-15. PubMed ID: 20660347
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral CpG-B Promotes Antitumoral Neutrophil, cDC, and T-cell Cooperation without Reprograming Tolerogenic pDC.
Humbert M; Guery L; Brighouse D; Lemeille S; Hugues S
Cancer Res; 2018 Jun; 78(12):3280-3292. PubMed ID: 29588348
[TBL] [Abstract][Full Text] [Related]
18. Analysis of DC Functions Using CD205-DTR Knock-In Mice.
Fukaya T; Takagi H; Uto T; Arimura K; Sato K
Methods Mol Biol; 2016; 1423():291-308. PubMed ID: 27142025
[TBL] [Abstract][Full Text] [Related]
19. TLR9 agonist enhances radiofrequency ablation-induced CTL responses, leading to the potent inhibition of primary tumor growth and lung metastasis.
Xu A; Zhang L; Yuan J; Babikr F; Freywald A; Chibbar R; Moser M; Zhang W; Zhang B; Fu Z; Xiang J
Cell Mol Immunol; 2019 Oct; 16(10):820-832. PubMed ID: 30467420
[TBL] [Abstract][Full Text] [Related]
20. TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection.
Jelinek I; Leonard JN; Price GE; Brown KN; Meyer-Manlapat A; Goldsmith PK; Wang Y; Venzon D; Epstein SL; Segal DM
J Immunol; 2011 Feb; 186(4):2422-9. PubMed ID: 21242525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
